Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 14/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2402576 | 0.88 | MTNR1A (0.44) | MKNK2KEAP1 | |
| SCHEMBL2368210 | 0.84 | MKNK2 (0.43) | MKNK2 | |
| SCHEMBL2369150 | 0.76 | MAPT (0.41) | KEAP1LMNASMN1; SMN2 | |
| SCHEMBL16335648 | 0.75 | ALDH1A1 (0.39) | MKNK2KEAP1 | |
| SCHEMBL2368790 | 0.75 | MKNK2 (0.52) | MKNK2 | |
| SCHEMBL15941404 | 0.72 | SMN1; SMN2 (0.47) | KEAP1SMN1; SMN2 | |
| SCHEMBL2368217 | 0.72 | MKNK2 (0.42) | MKNK2KEAP1 | |
| SCHEMBL21253499 | 0.72 | MKNK2 (0.48) | MKNK2 | |
| SCHEMBL16338608 | 0.72 | MKNK2 (0.48) | MKNK2 | |
| SCHEMBL968557 | 0.71 | ALDH1A1 (0.45) | MKNK2KEAP1EP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2539343-B1 | THIENOPYRIMIDINES CONTAINING A SUBSTITUTED ALKYL GROUP FOR PHARMACEUTICAL COMPOSITIONS | EVOTEC INTERNAT GMBH (DE) | 2015-12-30 | — | — | EP | disclosed |
| US-8853193-B2 | Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-07 | — | — | US | disclosed |
| EP-2539343-A1 | THIENOPYRIMIDINES CONTAINING A SUBSTITUTED ALKYL GROUP FOR PHARMACEUTICAL COMPOSITIONS | Boehringer Ingelheim International GmbH (DE) | 2013-01-02 | — | — | EP | disclosed |
| US-20110212103-A1 | THIENOPYRIMIDINES CONTAINING A SUBSTITUTED ALKYL GROUP FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | US | disclosed |
| WO-2011104340-A1 | THIENOPYRIMIDINES CONTAINING A SUBSTITUTED ALKYL GROUP FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212103-A1 | THIENOPYRIMIDINES CONTAINING A SUBSTITUTED ALKYL GROUP FOR PHARMACEUTICAL COMPOSITIONS | CMPK1, DTYMK, NEK2 | MKNK2 28/4885KEAP1 2793/4885EP300 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.